

Technology Advisory Committee C Interests Register

Topic: Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]

Publication Date: 14/12/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Matt Stevenson	Committee Member	Non-financial professional	Professor Stevenson works for SchARR, the ERG for this topic. He was not involved in the ERG's work.	N/A	14/09/2022	N/A	It was agreed his declaration would not prevent Professor Stevenson from participating in discussions on this appraisal.
Dr Richard Hubner	Clinical expert	Direct financial	Dr Richard Hubner has attended advisory boards for Roche, BMS, Eisai, Celgene, Beigene, Ipsen and BTG and received speaker fees from Eisai, Ipsen, Mylan and PrimeOncology. He has trial steering committee membership for Beigene and Ipsen and received conference attendance support from Bayer, BMS and Roche.	N/A	25/11/2021	N/A	It was agreed his declarations would not prevent Dr Hubner from providing expert advice to the committee
Professor Tim Meyer	Clinical expert	Financial	Professor Meyer has been paid as a consultant on advisory boards for Adaptimmune, AstraZeneca, BMS, Boston Scientific, Eisai, Ipsen and Roche, and	N/A	22/12/2021	N/A	It was agreed his declarations would not prevent Professor Meyer from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			received consultancy for Geneos.				
Vanessa Hebditch	Patient expert	Indirect financial	Ms Hebditch's employer, the British Liver Trust, has received an educational grant of £10,600 from Ipsen to produce patient materials for liver cancer patients and in support of raising awareness and launching these materials during Liver Cancer Awareness Month in October 2021. Ipsen had no control or influence over the content or promotion of these materials which were co-produced by patients, carers, and clinical experts.	N/A	28/03/2022	N/A	It was agreed her declaration would not prevent Ms Hebditch from providing expert advice to the committee.